Search This Blog

Thursday, April 16, 2026

Emergent BioSolutions refinances debt, extends maturities to April 2031 and lowers interest expense

 


  • Refinancing includes a new $150 million term loan from OrbiMed to support Emergent BioSolutions' capital structure.
  • An amended $50 million asset-based lending facility from Wells Fargo is part of Emergent BioSolutions' debt refinancing package.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)